Better Health for All

CAMP4 Therapeutics is entirely focused on developing regulatory RNA-targeting therapeutics to restore healthy protein levels and treat genetic diseases, addressing the root cause of over 1,200 haploinsufficient or partial loss-of-function disorders.

This includes rare and potentially fatal conditions like urea cycle disorders and neurodevelopmental SYNGAP1-related disorders, indicating a business model maximizing global health benefits. The company has secured a $17.5 million upfront payment from GSK for a collaboration, with eligibility for additional development and commercial milestone payments and tiered royalties, demonstrating significant investment in health innovation. The company targets rare genetic diseases, including SYNGAP1-related disorders, which represent 0.5% to 1.0% of all intellectual disability cases and currently lack FDA-approved, disease-modifying therapies, showing a focus on underserved populations. However, the company's press releases contain forward-looking statements that explicitly list multiple risks, including potential adverse events and regulatory approval risks. While a Phase 1 clinical trial for CMP-CPS-001 showed the treatment is safe and tolerable for humans, and GLP toxicology studies are underway for CMP-SYNGAP-01, specific adverse event rates are not provided. The company utilizes its RAP Platform to identify regulatory RNAs and has completed a Phase 1 clinical trial, implying adherence to ethical standards for clinical research, but no specific details on trial ethics are available.

Fair Pay & Worker Respect

The CEO's total compensation of $2.29 million (Q1 2025)

compared to an approximate average annual employee wage of $100,720 results in a pay ratio of 22.73:1. The company has reported zero fines or violations related to labor laws in the past two years, and states it is in material compliance with all applicable occupational health and safety laws.

Fair Trade & Ethical Sourcing

CAMP4 Therapeutics Corporation relies on third-party suppliers for manufacturing product candidates and raw materials, including two Chinese companies, Hongene Biotech and WuXi TIDES.

The company's Code of Business Conduct and Ethics, effective October 10, 2024, outlines ethical conduct in business dealings and interactions with suppliers, and mentions overseeing manufacturing and supply chains to ensure compliance with applicable laws and regulations, including good manufacturing practices. However, the provided articles do not contain specific, quantifiable data points regarding the percentage of fair-trade certified spend, supplier audit frequency, number of forced or child labor incidents, traceability coverage, remediation speed for violations, the percentage of supplier contracts with enforceable ethical-sourcing clauses, the share of spend on high-risk materials, or the percentage of procurement budget directed to diverse suppliers.

Honest & Fair Business

The company has a comprehensive whistleblower policy, effective October 10, 2024, which applies to all directors, officers, and employees.

It includes an anonymous, confidential hotline (833-545-2866) for reporting concerns regarding accounting, auditing, or code of conduct violations. The policy explicitly prohibits retaliation against employees who submit good faith complaints, and complaints are retained for at least seven years. Credible complaints are promptly communicated to the Chairperson of the Audit Committee, while non-credible complaints are communicated no less frequently than quarterly. The Audit Committee reviews and discusses with management the company’s procedures and practices designed to ensure compliance with anti-corruption laws, including the Foreign Corrupt Practices Act of 1977 and the UK Bribery Act 2010. The company's Code of Business Conduct and Ethics, also effective October 10, 2024, requires employees to act in accordance with its Anti-Corruption Compliance Policy and may require annual certification of compliance.

Kind to Animals

The company conducts preclinical and GLP toxicology studies for its drug candidates, such as CMP-002 and CMP-SYNGAP-01, using animal models including mice and non-human primates (cynomolgus monkeys).

There is no evidence of the use of non-animal testing methods. The company's Code of Business Conduct and Ethics and other articles explicitly state that no specific animal testing policy is mentioned. The company has tested ASOs upregulating human OTC in a humanized liver mouse model and in cynomolgus monkeys, indicating the use of animals for product testing.

No War, No Weapons

No specific, concrete evidence was found in the provided articles regarding CAMP4 Therapeutics Corporation's association with arms manufacturing, military contracts, or conflict facilitation.

All KPIs related to the 'No War, No Weapons' value lacked explicit data points, leading to their omission.

Planet-Friendly Business

The provided articles, primarily financial filings and corporate governance documents, do not contain specific, quantitative data points for any of the 'Planet-Friendly Business' KPIs for CAMP4 Therapeutics Corporation. While some articles discuss the broader biotech and pharma industry's environmental impacts or mention the company's governance committee overseeing environmental matters,

there is no direct evidence of CAMP4's own emissions, targets, renewable energy use, water consumption, waste diversion, certifications, or climate-related financial disclosures.

Respect for Cultures & Communities

The provided articles do not contain specific, concrete data points or actions related to CAMP.US's engagement with local communities, cultural preservation efforts, or any other metrics under the 'Respect for Cultures & Communities' value.

Information primarily focuses on internal corporate governance, ethical conduct, and legal compliance, without detailing community-specific initiatives or outcomes.

Safe & Smart Tech

No specific evidence was found in the provided articles regarding CAMP4 Therapeutics Corporation's performance across any of the 'Safe & Smart Tech' KPIs. The articles explicitly state 'No data on' or 'No mention of' for all relevant areas, including data breach severity, AI ethics governance, cybersecurity investment, privacy certifications, security training effectiveness, encryption implementation, AI audit practices, algorithmic transparency, unauthorized data use, user data control, authentication security, vulnerability management, bug bounty effectiveness, privacy by design, security testing coverage, data minimization, regulatory compliance (related to privacy), algorithmic harm remediation, and digital rights advocacy.

Information about clinical trial results is not relevant to privacy regulatory compliance.